BR0316962A - Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc - Google Patents

Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc

Info

Publication number
BR0316962A
BR0316962A BR0316962-6A BR0316962A BR0316962A BR 0316962 A BR0316962 A BR 0316962A BR 0316962 A BR0316962 A BR 0316962A BR 0316962 A BR0316962 A BR 0316962A
Authority
BR
Brazil
Prior art keywords
treatment
aminoalkoxyindols
receptor binders
disorders
snc
Prior art date
Application number
BR0316962-6A
Other languages
English (en)
Inventor
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32469485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0316962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0316962A publication Critical patent/BR0316962A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"AMINOALCOXIINDóIS COMO LIGANTES PARA O RECEPTOR DE 5-HT6 PARA O TRATAMENTO DE DISTúRBIOS DO SNC". A presente invenção fornece o composto da Fórmula (I): e sais ou pró-drogas farmaceuticamente aceitáveis do mesmo, em que R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, m e n são como definidos aqui. A invenção fornece ainda processos para a preparação, composições que compreendem e o uso de compostos da fórmula (I) para a produção de um medicamento para o tratamento de doenças mediadas por 5-HT6.
BR0316962-6A 2002-12-03 2003-11-27 Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc BR0316962A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43050602P 2002-12-03 2002-12-03
PCT/EP2003/013372 WO2004050085A1 (en) 2002-12-03 2003-11-27 Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders

Publications (1)

Publication Number Publication Date
BR0316962A true BR0316962A (pt) 2005-10-25

Family

ID=32469485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316962-6A BR0316962A (pt) 2002-12-03 2003-11-27 Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc

Country Status (24)

Country Link
US (1) US7084169B2 (pt)
EP (1) EP1569638B1 (pt)
JP (1) JP4339795B2 (pt)
KR (1) KR100755580B1 (pt)
CN (1) CN1713908B (pt)
AR (1) AR042155A1 (pt)
AT (1) ATE372113T1 (pt)
AU (1) AU2003289903B2 (pt)
BR (1) BR0316962A (pt)
CA (1) CA2508315A1 (pt)
DE (1) DE60316180T2 (pt)
ES (1) ES2291722T3 (pt)
HR (1) HRP20050457A2 (pt)
MX (1) MXPA05005790A (pt)
MY (1) MY138466A (pt)
NO (1) NO20052730L (pt)
NZ (1) NZ539950A (pt)
PA (1) PA8589801A1 (pt)
PE (1) PE20040763A1 (pt)
PL (1) PL377464A1 (pt)
RU (1) RU2350602C2 (pt)
TW (1) TWI284124B (pt)
WO (1) WO2004050085A1 (pt)
ZA (1) ZA200504412B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417142A (en) * 1992-12-18 1995-05-23 Caterpillar Inc. Hydraulic amplifier
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
WO2007084841A2 (en) * 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
MX2008013053A (es) 2006-04-12 2008-10-17 Wyeth Corp Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6.
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN102558020B (zh) * 2011-12-12 2013-09-18 温州大学 一种3-芳巯基吲哚类化合物的合成方法
CN103288707B (zh) * 2013-05-28 2015-12-23 浙江大学 一种3-苯巯基吲哚衍生物的制备方法
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1139760A (en) * 1979-03-07 1983-01-18 Makiko Sakai 1,4-dioxaspiro¬4,5| decene compounds
FR2589863B1 (fr) * 1985-11-12 1988-07-29 Sanofi Sa Derives d'hydroxy-4 indole, leur procede de preparation et leur utilisation
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US4939138A (en) * 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
JP2000516936A (ja) * 1996-08-27 2000-12-19 アメリカン・ホーム・プロダクツ・コーポレイション ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2791344B1 (fr) * 1999-03-25 2002-02-15 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) * 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002085853A2 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
AU2003289903A1 (en) 2004-06-23
JP4339795B2 (ja) 2009-10-07
MY138466A (en) 2009-06-30
PL377464A1 (pl) 2006-02-06
PE20040763A1 (es) 2004-11-20
JP2006509777A (ja) 2006-03-23
RU2005121125A (ru) 2006-02-20
ES2291722T3 (es) 2008-03-01
EP1569638B1 (en) 2007-09-05
TWI284124B (en) 2007-07-21
ATE372113T1 (de) 2007-09-15
US20040132799A1 (en) 2004-07-08
TW200413312A (en) 2004-08-01
HRP20050457A2 (en) 2005-10-31
KR100755580B1 (ko) 2007-09-06
PA8589801A1 (es) 2004-11-26
ZA200504412B (en) 2006-04-26
CN1713908A (zh) 2005-12-28
RU2350602C2 (ru) 2009-03-27
EP1569638A1 (en) 2005-09-07
DE60316180T2 (de) 2008-05-29
KR20050084155A (ko) 2005-08-26
NO20052730L (no) 2005-08-23
DE60316180D1 (de) 2007-10-18
US7084169B2 (en) 2006-08-01
MXPA05005790A (es) 2005-10-18
NZ539950A (en) 2007-05-31
NO20052730D0 (no) 2005-06-07
WO2004050085A1 (en) 2004-06-17
AR042155A1 (es) 2005-06-08
CN1713908B (zh) 2010-05-12
AU2003289903B2 (en) 2008-06-26
CA2508315A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
BR0316962A (pt) Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0207172A (pt) Pirido-pirimidinas 6-substituìdas
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
BR0209056A (pt) Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
BR0315302A (pt) Benzoxazinonas substituìdas e seus usos
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
BR0113590A (pt) 7-oxo-piridopirimidinas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.